Spiro Medical Secures $67M to Revolutionize Asthma Treatment with PNM System
January 13, 2026, 4:00 am
Location: United States, California, Menlo Park
Employees: 11-50
Founded date: 2005
Spiro Medical secured $67 million in Series A funding. This capital fuels development of its innovative Pulmonary Neuromodulation System (PNM). PNM offers a novel, drug-free approach for severe asthma. It uses mild electrical impulses to control symptoms. The system targets millions suffering from chronic lung disease. Funds will advance system development and critical clinical work. Spiro Medical seeks US regulatory approval. Major investors led this significant round. This investment signifies a pivotal moment. It promises to redefine asthma treatment. The technology addresses airway nerve pathways. Spiro Medical aims to profoundly impact patient lives. This breakthrough represents healthcare innovation.
Spiro Medical, a pioneering medtech company, has closed a significant $67 million Series A equity financing round. This substantial investment propels the development of its groundbreaking Pulmonary Neuromodulation System (PNM). The Irvine, California-based firm focuses on a novel, drug-free approach for severe asthma treatment. This funding marks a pivotal moment for chronic lung disease management. It signals a new era for patients seeking innovative solutions.
The PNM system represents a first-of-its-kind technology. It utilizes mild electrical impulses. These impulses control symptoms associated with asthma. The system targets airway nerves and neural reflex pathways. This mechanism differs significantly from traditional drug therapies. It offers a unique alternative for individuals with severe asthma. Millions worldwide grapple with this chronic condition. Spiro Medical aims to provide profound relief.
Funding proceeds will support several critical initiatives. A primary goal is the development of a purpose-built PNM system. This involves extensive research and engineering. The company will also execute crucial clinical work. These trials are essential for demonstrating safety and efficacy. Ultimately, Spiro Medical seeks regulatory approval in the United States. This approval will pave the way for broader patient access.
A syndicate of prominent venture investors led the Series A round. Andera Partners, Omega Funds, and Sherpa Healthcare Partners were key leaders. Additional participation came from HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd UK. This diverse group of investors underscores confidence in Spiro Medical’s vision. It validates the potential of neuromodulation technology.
Asthma remains a significant global health challenge. Over 28 million people in the U.S. suffer from asthma. Worldwide, the number exceeds 300 million. Symptoms include wheezing, shortness of breath, chest tightness, and coughing. Current treatments often involve inhalers and medications. However, severe asthma patients frequently experience uncontrolled symptoms. They require more advanced interventions. The PNM system offers a hopeful new path.
Pulmonary neuromodulation provides a distinct approach. It directly targets the neurological basis of asthma symptoms. By modulating nerve activity, the system aims to reduce airway hypersensitivity. This could lead to fewer exacerbations. It may also improve overall lung function. The drug-free nature of PNM offers another advantage. It avoids potential side effects associated with long-term medication use.
The company's leadership brings extensive expertise. Spiro Medical was founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D. Their combined experience in medicine, research, and implantable neuromodulation systems is critical. This strong foundation positions Spiro Medical for successful development and commercialization. The team’s vision centers on transforming patient care.
Neuromodulation is an emerging field in medicine. It involves altering nerve activity through targeted electrical stimulation. This technology has shown promise in various medical conditions. Spiro Medical applies this principle to pulmonary diseases. Beyond asthma, the PNM system may hold potential for chronic cough and COPD. These conditions also involve complex nerve interactions in the airways. Exploring these broader applications will be part of future development.
The investment round also saw key additions to Spiro Medical's board of directors. Raphaël Wisniewski, Claudio Nessi, and Ouyang Xiangyu now serve on the board. Their collective experience in healthcare investment and strategy will guide the company. This strengthens Spiro Medical's leadership and strategic direction. It ensures robust oversight for the ambitious development roadmap.
Clinical trials are the next vital step. These studies will assess the safety and effectiveness of the PNM system. Rigorous testing is necessary to meet regulatory standards. Successful trials will lead to FDA approval. This approval is essential for widespread adoption in the US market. Spiro Medical is committed to delivering a well-validated and impactful therapy.
The company's focus on an implantable system highlights its commitment to a long-term solution. Implantable devices offer continuous therapy. They reduce the burden of daily medication adherence. Patients could experience sustained symptom control. This greatly enhances quality of life. Such innovation addresses a significant unmet medical need.
Spiro Medical's Series A funding underscores the growing interest in advanced medtech solutions. Investors recognize the immense market potential. They see the transformative impact of neuromodulation in chronic disease management. This financial boost empowers Spiro Medical to accelerate its mission. The company aims to bring its innovative PNM system to patients swiftly and safely. The future of asthma treatment appears brighter with this new development.
Spiro Medical, a pioneering medtech company, has closed a significant $67 million Series A equity financing round. This substantial investment propels the development of its groundbreaking Pulmonary Neuromodulation System (PNM). The Irvine, California-based firm focuses on a novel, drug-free approach for severe asthma treatment. This funding marks a pivotal moment for chronic lung disease management. It signals a new era for patients seeking innovative solutions.
The PNM system represents a first-of-its-kind technology. It utilizes mild electrical impulses. These impulses control symptoms associated with asthma. The system targets airway nerves and neural reflex pathways. This mechanism differs significantly from traditional drug therapies. It offers a unique alternative for individuals with severe asthma. Millions worldwide grapple with this chronic condition. Spiro Medical aims to provide profound relief.
Funding proceeds will support several critical initiatives. A primary goal is the development of a purpose-built PNM system. This involves extensive research and engineering. The company will also execute crucial clinical work. These trials are essential for demonstrating safety and efficacy. Ultimately, Spiro Medical seeks regulatory approval in the United States. This approval will pave the way for broader patient access.
A syndicate of prominent venture investors led the Series A round. Andera Partners, Omega Funds, and Sherpa Healthcare Partners were key leaders. Additional participation came from HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd UK. This diverse group of investors underscores confidence in Spiro Medical’s vision. It validates the potential of neuromodulation technology.
Asthma remains a significant global health challenge. Over 28 million people in the U.S. suffer from asthma. Worldwide, the number exceeds 300 million. Symptoms include wheezing, shortness of breath, chest tightness, and coughing. Current treatments often involve inhalers and medications. However, severe asthma patients frequently experience uncontrolled symptoms. They require more advanced interventions. The PNM system offers a hopeful new path.
Pulmonary neuromodulation provides a distinct approach. It directly targets the neurological basis of asthma symptoms. By modulating nerve activity, the system aims to reduce airway hypersensitivity. This could lead to fewer exacerbations. It may also improve overall lung function. The drug-free nature of PNM offers another advantage. It avoids potential side effects associated with long-term medication use.
The company's leadership brings extensive expertise. Spiro Medical was founded by Stephen Pyles, M.D., Kurt Gehlsen, M.D., Ph.D., Rinda Sama, and G. Jay Jiang, Ph.D. Their combined experience in medicine, research, and implantable neuromodulation systems is critical. This strong foundation positions Spiro Medical for successful development and commercialization. The team’s vision centers on transforming patient care.
Neuromodulation is an emerging field in medicine. It involves altering nerve activity through targeted electrical stimulation. This technology has shown promise in various medical conditions. Spiro Medical applies this principle to pulmonary diseases. Beyond asthma, the PNM system may hold potential for chronic cough and COPD. These conditions also involve complex nerve interactions in the airways. Exploring these broader applications will be part of future development.
The investment round also saw key additions to Spiro Medical's board of directors. Raphaël Wisniewski, Claudio Nessi, and Ouyang Xiangyu now serve on the board. Their collective experience in healthcare investment and strategy will guide the company. This strengthens Spiro Medical's leadership and strategic direction. It ensures robust oversight for the ambitious development roadmap.
Clinical trials are the next vital step. These studies will assess the safety and effectiveness of the PNM system. Rigorous testing is necessary to meet regulatory standards. Successful trials will lead to FDA approval. This approval is essential for widespread adoption in the US market. Spiro Medical is committed to delivering a well-validated and impactful therapy.
The company's focus on an implantable system highlights its commitment to a long-term solution. Implantable devices offer continuous therapy. They reduce the burden of daily medication adherence. Patients could experience sustained symptom control. This greatly enhances quality of life. Such innovation addresses a significant unmet medical need.
Spiro Medical's Series A funding underscores the growing interest in advanced medtech solutions. Investors recognize the immense market potential. They see the transformative impact of neuromodulation in chronic disease management. This financial boost empowers Spiro Medical to accelerate its mission. The company aims to bring its innovative PNM system to patients swiftly and safely. The future of asthma treatment appears brighter with this new development.